The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses [CMS-4180-P]” published in the Federal Register on November 30, 2018.
On January 25, 2019, AMCP provided comments to CMS in response to the proposed rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses. AMCP offered comments on the following CMS proposals; Providing Plan Flexibility to Manage Protected Classes; Prohibition Against Gag Clauses in Pharmacy Contracts; E-Prescribing and the Part D Prescription Drug Program; Updating Part D E-Prescribing Standards; Part D Explanation of Benefits; and Medicare Advantage and Step Therapy for Part B Drugs.
Findings from this review indicate that health care providers approach biosimilars with caution due to limited knowledge, low prescribing comfort, and concerns over safety and efficacy. The authors of this JMCP article recommend clinician-directed education to realize the full cost-saving potential of biosimilars.
HIV positive patients on single tablet regimens have better adherence and lower inpatient health costs, according to a retrospective claims data analysis published in JMCP.
AMCP CEO Blog: Thoughts on Digital Therapeutics. These therapeutics offer the potential to revolutionize population health management and help patients live healthier lives.
January 2019 News & Views: New President-elect, Treasurer and Two Directors; CEO Blog: Cost-Effectiveness of MTM Programs; Help AMCP Plan Educational Programming